Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2.
Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2.
复制标题
DOI：
10.3390/vaccines8030474
复制
发表时间：
2020-08-25
期刊：
影响因子：
7.8
通讯作者：
Gamarra LF
中科院分区：
文献类型：
--
作者：
Rego GNA;Nucci MP;Alves AH;Oliveira FA;Marti LC;Nucci LP;Mamani JB;Gamarra LF
2019冠状病毒病（COVID-19）是21世纪世纪最大的健康挑战，影响全球数百万人。由于缺乏广泛有效的COVID-19治疗方法或SARS-CoV-2传播预防策略，严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的爆发引发了科学界在不同平台上开发新疫苗的前所未有的努力。基于从主要临床试验数据库中选择的50项当前研究，本系统性综述总结了全球COVID-19疫苗开发竞赛。对于每项研究，突出显示了主要的干预特征、使用的设计以及创建的当地或全球中心合作伙伴关系。大多数疫苗的开发是在亚洲进行的，使用的是病毒载体方法。两种纯化的灭活SARS-CoV-2候选疫苗，一种基于mRNA的疫苗mRNA 1273和黑猩猩腺病毒疫苗ChAdOx 1目前正在巴西、阿拉伯联合酋长国、美国和英国进行III期临床试验。这些疫苗是在一个迅速形成的合作网络的基础上开发的。
Coronavirus disease 2019 (COVID-19) is the biggest health challenge of the 21st century, affecting millions of people globally. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has ignited an unprecedented effort from the scientific community in the development of new vaccines on different platforms due to the absence of a broad and effective treatment for COVID-19 or prevention strategy for SARS-CoV-2 dissemination. Based on 50 current studies selected from the main clinical trial databases, this systematic review summarizes the global race for vaccine development against COVID-19. For each study, the main intervention characteristics, the design used, and the local or global center partnerships created are highlighted. Most vaccine developments have taken place in Asia, using a viral vector method. Two purified inactivated SARS-CoV-2 vaccine candidates, an mRNA-based vaccine mRNA1273, and the chimpanzee adenoviral vaccine ChAdOx1 are currently in phase III clinical trials in the respective countries Brazil, the United Arab Emirates, the USA, and the United Kingdom. These vaccines are being developed based on a quickly formed network of collaboration.
影响因子：
5.5
作者：
Alharbi NK;Padron-Regalado E;Thompson CP;Kupke A;Wells D;Sloan MA;Grehan K;Temperton N;Lambe T;Warimwe G;Becker S;Hill AVS;Gilbert SC
通讯作者：
Gilbert SC
影响因子：
4.7
作者：
Ahmed, Syed Faraz;Quadeer, Ahmed A.;McKay, Matthew R.
通讯作者：
McKay, Matthew R.